{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NICOLAS","nct_id":"NCT02434081","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nicolas-nct02434081. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NICOLAS","arms":[{"description":"4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.","label":"Chemo-radiotherapy with concurrent nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb","Frontier Science Foundation, Hellas"],"completion_date":{"date":"2020-03-31","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer Stage III"],"enrollment":{"count":94,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["BMS-936558"],"type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"ETOP IBCSG Partners Foundation","official_title":"A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-02-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy","timeFrame":"Time from enrolment until 6 months post-radiotherapy"}],"references":[{"citation":"Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10;31(8):1029-38. doi: 10.1200/JCO.2012.44.5064. Epub 2013 Feb 11.","pmid":"23401449","type":"BACKGROUND"},{"citation":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.","pmid":"28551359","type":"BACKGROUND"}],"start_date":{"date":"2015-11-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma","url":"https://clinicaltrials.gov/study/NCT02434081"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nicolas-nct02434081"}